You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION (provided by applicant): Research and Related Other Project Information Item 7. Project Summary/Abstract Neurodegeneration in Alzheimer's disease (AD) may result from deposition of A as plaques in brain tissue. However, less effort has been made to elucidate the role of tau- containing neurofibrillary tangles (NFTs) in AD. Accumulating evidence suggests that tau containing NFTs i ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Devices enabling improved light delivery for photodynamic therapy of oral cancer

    SBC: LUCIFICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Oral cancer is a devastating disease that impacts 640,000 people worldwide. Though treatment with photodynamic therapy can be effective with significantly less morbidity than alternative therapies, problems arising fromless than optimal light delivery to the oral cavity have hindered its widespread application. The goal of the proposed research is to provide a ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): In the United States colorectal cancer (CRC) is the third leading cause of cancer mortality. Surgery is the primary treatment for early stage CRC; but adjuvant therapy is usually needed in advanced disease. Approximately 55% of CRC patients have metastatic disease for which the prognosis is poor despite incremental improvements due to introduction of irinotecan ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St

    SBC: INTICA BIOMEDICAL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This project is designed to allow independent experts in the development and/or application of in vitro breast cancer diagnostic tests, Drs. Badve (breast pathologist) and Sledge (breast oncologist), to evaluate INTICA's candidate anti-DEspR mAbs to develop the preliminary materials and methods for a commercially viable companion diagnostic test. DEspR, th ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Phase 1 Safety and Pharmacokinetics of ALK001 in people over 60

    SBC: ALKEUS PHARMACEUTICALS, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): The overall goal of this collaborative research between Alkeus Pharmaceuticals and Columbia University Medical Center is to evaluate a new oral investigational treatment for dry age-related macular degeneration (dry-AMD), the leading cause of blindness in the U.S., and Stargardt's disease, also known as juvenile macular degeneration. The investigational co ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. GPU Accelerated Protein Docking Software with Flexible Refinement

    SBC: ACPHARIS            Topic: NIGMS

    DESCRIPTION (provided by applicant): Protein-protein interactions are involved at multiple points in virtually all biological pathways. Understanding such interactions is also important for the design of biologics that can target extracellular receptors with high affinity and specificity. Since determining the structure of protein complexes by X-ray crystallography is expensive and slow, it is im ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Non-invasive neonatal respiration monitor

    SBC: FLUOROMETRIX CORPORATION            Topic: NICHD

    DESCRIPTION (provided by applicant): Preterm birth requires technologies for supporting immature organ systems on one hand while minimizing technology-induced injury on the other that may contribute to long-term adverse outcomes. Specific problems of thiskind are extremes in arterial partial pressure of oxygen and carbon dioxide. A variety of pathological conditions are known to result from both ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Next Generation Therapeutics for Hemoglobinopathies

    SBC: Phoenicia Biosciences, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Sickle cell disease and 2-thalassemias are mankind's most common hereditary monogenic diseases, comprise a major global health burden, and cost the US healthcare system gt 1 billion annually. Patients have chronic disabling morbidity and early mortality. Fetal hemoglobin (HbF: a2,g2) is another endogenous type of hemoglobin normally present in all humans, ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government